scholarly journals Association between Serotonin Transporter-Linked Polymorphic Region and Escitalopram Antidepressant Treatment Response in Korean Patients with Major Depressive Disorder

2012 ◽  
Vol 66 (4) ◽  
pp. 221-229 ◽  
Author(s):  
Eun-Soo Won ◽  
Hun-Soo Chang ◽  
Hwa-Young Lee ◽  
Byung-Joo Ham ◽  
Min-Soo Lee
Keyword(s):  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Treatment Response ◽  
Serotonin Transporter ◽  
Antidepressant Treatment ◽  
Polymorphic Region ◽  
Major Depressive ◽  
Korean Patients

scholarly journals Remote Digital Measurement of Facial and Vocal Markers of Major Depressive Disorder Severity and Treatment Response: A Pilot Study

2021 ◽  
Vol 3 ◽  
Author(s):  
Anzar Abbas ◽  
Colin Sauder ◽  
Vijay Yadav ◽  
Vidya Koesmahargyo ◽  
Allison Aghjayan ◽  
...  
Keyword(s):  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Treatment Response ◽  
Head Movement ◽  
Selective Serotonin Reuptake Inhibitors ◽  
Rating Scale ◽  
Antidepressant Treatment ◽  
Digital Measurement ◽  
Major Depressive ◽  
Patient Responses

Objectives: Multiple machine learning-based visual and auditory digital markers have demonstrated associations between major depressive disorder (MDD) status and severity. The current study examines if such measurements can quantify response to antidepressant treatment (ADT) with selective serotonin reuptake inhibitors (SSRIs) and serotonin–norepinephrine uptake inhibitors (SNRIs).Methods: Visual and auditory markers were acquired through an automated smartphone task that measures facial, vocal, and head movement characteristics across 4 weeks of treatment (with time points at baseline, 2 weeks, and 4 weeks) on ADT (n = 18). MDD diagnosis was confirmed using the Mini-International Neuropsychiatric Interview (MINI), and the Montgomery–Åsberg Depression Rating Scale (MADRS) was collected concordantly to assess changes in MDD severity.Results: Patient responses to ADT demonstrated clinically and statistically significant changes in the MADRS [F(2, 34) = 51.62, p < 0.0001]. Additionally, patients demonstrated significant increases in multiple digital markers including facial expressivity, head movement, and amount of speech. Finally, patients demonstrated significantly decreased frequency of fear and anger facial expressions.Conclusion: Digital markers associated with MDD demonstrate validity as measures of treatment response.

231. Serotonin Transporter Gene Methylation and Antidepressant Treatment of Major Depressive Disorder

2017 ◽  
Vol 81 (10) ◽  
pp. S95
Author(s):  
Amanda Lisoway ◽  
Clement C. Zai ◽  
Arun K. Tiwari ◽  
Ricardo Harripaul ◽  
Natalie Freeman ◽  
...  
Keyword(s):  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Serotonin Transporter ◽  
Antidepressant Treatment ◽  
Serotonin Transporter Gene ◽  
Transporter Gene ◽  
Gene Methylation ◽  
Major Depressive

scholarly journals Remote digital measurement of visual and auditory markers of Major Depressive Disorder severity and treatment response.

2020 ◽  
Author(s):  
Isaac Galatzer-Levy ◽  
Anzar Abbas ◽  
Vijay Yadav ◽  
Vidya Koesmahargyo ◽  
Allison Aghjayan ◽  
...  
Keyword(s):  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Treatment Response ◽  
Head Movement ◽  
Selective Serotonin Reuptake Inhibitors ◽  
Rating Scale ◽  
Antidepressant Treatment ◽  
Digital Measurement ◽  
Major Depressive ◽  
Patient Responses

Objectives: Multiple machine learning-based visual and auditory digital markers have demonstrated associations between Major Depressive Disorder (MDD) status and severity. The current study examines if such measurements can quantify response to antidepressant treatment (ADT) with selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine uptake inhibitors (SNRIs). Methods: Visual and auditory markers were acquired through an automated smartphone task that measures facial, vocal, and head movement characteristics across the first five weeks of treatment (with timepoints at 1, 3, and 5 weeks) on ADT (n = 12). The Montgomery-Asberg Depression Rating Scale (MADRS) was collected concordantly through clinical interviews to confirm diagnosis and assess changes in MDD severity. Results: Patient responses to ADT demonstrated clinically and statistically significant changes in the MADRS F(2,34) = 51.62, p <.0001. Additionally, patients demonstrated significant increases in multiple digital markers including facial expressivity, head movement, and amount of speech. Finally, patients demonstrated significant decreased frequency of fear and anger facial expressions. Conclusion: Digital markers associated with MDD demonstrate validity as measures of treatment response.

scholarly journals Uncovering the Roles of MicroRNAs in Major Depressive Disorder: From Candidate Diagnostic Biomarkers to Treatment Response Indicators

Life ◽  
2021 ◽  
Vol 11 (10) ◽  
pp. 1073
Author(s):  
Claudia Homorogan ◽  
Diana Nitusca ◽  
Edward Seclaman ◽  
Virgil Enatescu ◽  
Catalin Marian
Keyword(s):  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Treatment Response ◽  
Current Knowledge ◽  
Antidepressant Treatment ◽  
Response Monitoring ◽  
Major Depressive ◽  
Diagnostic Biomarkers ◽  
Potential Biomarker ◽  
Pathological Mechanism

Major depressive disorder (MDD) is a recurrent debilitating illness that represents a major health burden due to its increasing worldwide prevalence, unclear pathological mechanism, nonresponsive treatment, and lack of reliable and specific diagnostic biomarkers. Recently, microRNA species (miRs) have gained particular interest because they have the ability to post-transcriptionally regulate gene expression by modulating mRNA stability and translation in a cohesive fashion. By regulating entire genetic circuitries, miRs have been shown to have dysregulated expression levels in blood samples from MDD patients, when compared to healthy subjects. In addition, antidepressant treatment (AD) also appears to alter the expression pattern of several miRs. Therefore, we critically and systematically reviewed herein the studies assessing the potential biomarker role of several candidate miRs for MDD, as well as treatment response monitoring indicators, in order to enrich the current knowledge and facilitate possible diagnostic biomarker development for MDD, which could aid in reducing both patients’ burden and open novel avenues toward a better understanding of MDD neurobiology.

Sign in / Sign up

Export Citation Format

Share Document